DUBLIN, February 15, 2022 /PRNewswire/ — Perrigo Company plc (NYSE; TASE: PRGO) today announced that it will report its fourth quarter and full year 2021 financial results on Tuesday, March 1, 2022. The Company will also hold a conference call from 8:30 a.m. (EST).

Perrigo Company. (PRNewsfoto/Perrigo Company plc)

The conference call will be available live via webcast to interested parties on the investor relations section of Perrigo’s website at http://perrigo.investorroom.com/events-webcasts or by phone at 888-317-6003, International 412-317-6061, and reference ID # 3221228. A recorded replay of the call will be available from approximately 12:00 p.m. (EST) TuesdayMarch 1, until midnight Tuesday, March 8, 2022. To listen to the replay, dial 877-344-7529, International 412-317-0088 and use passcode 1209247.

About Perrigo

Perrigo Company plc (NYSE; TASE: PRGO) is a leading provider of quality, affordable self-care products and over-the-counter health and wellness solutions that enhance individual well-being by enabling consumers to proactively prevent or treat conditions. which can be self-managed. Led by its consumer self-care strategy, Perrigo is the largest store brand OTC player in the United States in the categories in which it competes across more than 9,000 SKUs under “own brand” labels. of customer. Additionally, Perrigo is one of the top 10 OTC companies by revenue in Europe, where it markets more than 200 branded OTC products in 28 countries. Visit Perrigo online at www.perrigo.com.

Perrigo forward-looking statements

Certain statements contained in this press release are “forward-looking statements”. These statements relate to future events or the future financial performance of the Company and involve known and unknown risks, uncertainties and other factors that could cause the results, levels of activity, performance or actual achievements of the Company or its industry are materially different from those expressed or implied by forward-looking statements. In some instances, forward-looking statements may be identified by words such as “may”, “will”, “could”, “would”, “should”, “expect”, “anticipate”, “plan”, “anticipates,” “intends,” “believes,” “estimates,” “predicts,” “potential” or the negative form of these terms or other comparable terminology. The Company has based these forward-looking statements on its expectations Current expectations, assumptions, estimates and projections.While the Company believes these expectations, assumptions, estimates and projections to be reasonable, these forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond the control of the Company. Company, including: the effect of the coronavirus (COVID -19) pandemic and its variants and associated supply chain impacts on the Company’s business; general economic, credit and market conditions; the expenses of dep future termination; customer acceptance of new products; competition from other industry players, some of whom have greater marketing resources or greater market share in certain product categories than the Company; pricing pressures from customers and consumers; the resolution of uncertain tax positions, including the Company’s appeal regarding draft and final Notices of Proposal Assessment (“NOPA”) issued by the U.S. Internal Revenue Service and the impact that an adverse outcome in such a proceeding would have an impact on results of operations, cash flow, and liquidity; pending and potential third party claims and litigation, including litigation related to the Company’s restatement of previously filed financial information and litigation related to uncertain tax positions, including NOPAs; the potential impacts of ongoing or future governmental investigations and regulatory initiatives; the potential costs and reputational impact of product recalls or discontinued sales; the impact of tax reform and health policy; the timing, amount and cost of any share buybacks; fluctuations in currency exchange rates and interest rates; the Company’s ability to realize the expected benefits from the sale of its Rx business and the risk that potential costs or liabilities incurred or retained in connection with such transaction may exceed the Company’s estimates or adversely affect the business or operations of the society ; the completion and success of the proposed acquisition of HRA Pharma and the ability to derive the expected benefits, including the risk that the parties may not obtain required regulatory approvals or meet other closing conditions on time expected or not at all, the occurrence of any other event, change or circumstance that could delay the transaction or lead to the termination of the securities sale agreement or the risks that the Company’s synergies estimates will be inaccurate or that the Company will face higher than expected integration or other costs in connection with the proposed acquisition; the completion and success of other announced and unannounced acquisitions or divestitures, and the Company’s ability to realize the desired benefits thereof; and the Company’s ability to execute and achieve the desired benefits of announced cost reduction efforts and strategic and other initiatives. An adverse outcome with respect to the Company’s appeal of any material unpaid tax assessments or pending litigation, including securities or drug pricing issues, may ultimately require the use of assets of the Company to pay such dues, damages arising from third party claims and interest and/or penalties, and such use of Company assets would limit the assets available for other Company purposes . These and other important factors, including those discussed under “Risk Factors” in the company’s Form 10-K for the year ended December 31, 2020, as well as the Company’s subsequent filings with the United States Securities and Exchange Commission, may cause actual results, performance or achievements to differ materially from those expressed or implied by such forward-looking statements. The forward-looking statements contained in this press release are made only as of the date hereof and, except as otherwise required by applicable securities laws, the Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.



View original content to download multimedia: https://www.prnewswire.com/news-releases/perrigo-to-release-fourth-quarter-and-fiscal-year-2021-financial-results-on-march-1 -2022-301483092.html

SOURCEPerrigo Company plc